RxTrials Institute Drug Pipeline Alert
Dec. 6, 2007 | Vol. 5 No. 238
Data from two Phase III trials indicate Procter & Gamble’s (P&G) Asacol is effective and well tolerated in patients with different forms of ulcerative colitis, including isolated proctitis.
Australian biotechnology company Arana Therapeutics will begin a three-month Phase IIa study of ART621 in psoriasis patients and a Phase II study in rheumatoid arthritis.
Genzyme has enrolled all patients in a Phase II trial examining the safety and effectiveness of Clolar in previously untreated elderly patients with acute myelogenous leukemia (AML) who are unlikely to benefit from standard induction therapy.
Oculus Innovative Sciences has finished enrollment of its Phase II trial of Microcyn for the treatment of mildly infected diabetic foot ulcers.
Lexicon Pharmaceuticals has begun dosing in a Phase IIa trial with LX6171, an oral drug candidate for the treatment of cognitive impairment associated with disorders such as Alzheimer’s disease, schizophrenia and vascular dementia.
Celtic Pharmaceutical Holdings reported interim study results for an open-label extension trial for Xerecept as a treatment for tumor-related brain swelling.
United Therapeutics and its subsidiary Unither Pharmaceuticals have completed two trials of OvaRex MAb for the treatment of advanced ovarian cancer, and preliminary analysis demonstrates the studies failed to reach statistical significance.
Pfizer and Adolor have entered signed an agreement to develop ADL5859 and ADL5747 for the treatment of pain.
Centocor and Belgian drugmaker Janssen-Cilag International have submitted applications requesting the approval of ustekinumab in the U.S. and Europe for the treatment of adult patients with chronic moderate to severe plaque psoriasis.
ePublishing :: CMS, Hosting & Web Development | © Copyright by FDAnewsAll rights reserved. Do not duplicate or redistribute in any form.